Live tape
Top 8, mentions 7d13,386TSLA3,041 mentions▲ +0.05SPCX2,592 mentions▲ +0.08GOOGL1,788 mentions▲ +0.03META1,437 mentions▲ +0.05CRWV1,266 mentions▲ +0.04NVDA1,179 mentions▲ +0.07QQQ1,135 mentions▲ +0.05NFLX948 mentions▲ +0.03

Equity · Healthcare

NBIX

NASDAQ

Neurocrine Biosciences (NBIX)

$157 +1.21% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Sep 10, 2026
Price · Chart
26 sessions
$170 $150 5 Aug 10 Sep

The line runs $161 on 5 August through $157 on 10 September, on a scale from $150 to $170. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView TradingView chart · our licensed closes: 26 sessions, 5 Aug – 10 Sep 2026
Market cap $16.0B
P/E (TTM) 23.0
52-week range $123 – $181
Avg volume 113.6K

as of Sep 10, 2026

Neurocrine Biosciences (NBIX) insider trades

SEC Form 4 · last 90 days · newest reported trade 14 Sep 2026

In the 90 days to 22 Oct 2026, Neurocrine Biosciences insiders reported 4 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 13 Feb 2026, show no open-market purchase.

Open-market buys 0
Open-market sells 4
Net sold $1.05M
Non-trade filings 24
Date Insider Type Shares Value
14 Sep 2026 ABERNETHY MATT Chief Financial Officer Sell 2,311 $363K
14 Sep 2026 Boyer David W. Chief Corp. Affairs Officer Sell 826 $130K
09 Sep 2026 BENEVICH ERIC Chief Commercial Officer Sell 2,154 $333K
28 Jul 2026 Norwalk Leslie V Director Sell 1,250 $228K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
11 Sep 2026 ABERNETHY MATT Chief Financial Officer Award 5,020
11 Sep 2026 ABERNETHY MATT Chief Financial Officer Tax withheld 2,709 $423K
11 Sep 2026 BENEVICH ERIC Chief Commercial Officer Award 6,275
11 Sep 2026 BENEVICH ERIC Chief Commercial Officer Tax withheld 3,386 $529K
11 Sep 2026 Boyer David W. Chief Corp. Affairs Officer Award 3,587
11 Sep 2026 Boyer David W. Chief Corp. Affairs Officer Tax withheld 1,936 $302K
11 Sep 2026 Cooke Julie Chief Human Resources Officer Award 3,587
11 Sep 2026 Cooke Julie Chief Human Resources Officer Tax withheld 1,936 $302K
11 Sep 2026 Delaet Ingrid Chief Regulatory Officer Award 4,483
11 Sep 2026 Delaet Ingrid Chief Regulatory Officer Tax withheld 2,419 $378K
11 Sep 2026 GORMAN KEVIN CHARLES Director Award 14,343
11 Sep 2026 GORMAN KEVIN CHARLES Director Tax withheld 7,839 $1.22M

Showing the 12 most recent of 24 compensation filings in this window. The figures above count all of them.

Neurocrine Biosciences (NBIX) reported financials

SEC EDGAR XBRL SEC EDGAR

Neurocrine Biosciences reported revenue of $2.9B for the fiscal year ended 31 Dec 2025. Net income over the same period was $478.6M.

Figure Reported Period
Revenue $2.9B 31 Dec 2025 fiscal year
Net income $478.6M 31 Dec 2025 fiscal year
Diluted EPS $4.67 31 Dec 2025 fiscal year
Total assets $5.4B 30 Jun 2026 at period end
Total equity $3.7B 30 Jun 2026 at period end

Neurocrine Biosciences (NBIX) earnings

SEC EDGAR

Neurocrine Biosciences last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of $1.39; no next date is announced in SEC filings yet.

Date Period EPS Revenue
30 Jun 2026 Q2 2026 $1.39 —
31 Mar 2026 Q1 2026 $1.91 —
31 Dec 2025 FY 2025 $4.67 —
30 Sep 2025 Q3 2025 $2.04 —
30 Jun 2025 Q2 2025 $1.06 —
31 Mar 2025 Q1 2025 $0.08 —
31 Dec 2024 FY 2024 $3.29 —
30 Sep 2024 Q3 2024 $1.24 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

Neurocrine Biosciences (NBIX) institutional holders (13F)

SEC Form 13F SEC EDGAR

10 of the 45 institutional funds we track reported a Neurocrine Biosciences position for the quarter ended 30 Jun 2026 — a combined $1.6B; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
AQR Capital Management Held (±25%) −22.7% shares 3,818,037 $643.5M
Renaissance Technologies Held (±25%) −3.4% shares 2,335,897 $393.7M
Two Sigma Investments Trimmed −32.2% shares 2,076,260 $349.9M
Man Group Added +44.5% shares 601,019 $101.3M
Marshall Wace Trimmed −46.8% shares 270,754 $45.6M
Bridgewater Associates Added +38.8% shares 205,677 $34.7M
Fisher Asset Management Held (±25%) +10.5% shares 135,104 $22.8M
Citadel Advisors Trimmed −79.5% shares 11,863 $2.0M
Millennium Management Trimmed −99.1% shares 11,585 $2.0M
D. E. Shaw & Co. Trimmed −93.7% shares 5,599 $944K

Neurocrine Biosciences (NBIX) fails-to-deliver

SEC CNS data SEC

On 11 Sep 2026, 1,221 shares of Neurocrine Biosciences failed to deliver (about $191K).

Settlement date Shares failed Notional % of shares out
11 Sep 2026 1,221 $191K 0.001%
09 Sep 2026 11 $2K <0.001%
08 Sep 2026 19 $3K <0.001%

Congressional trades in Neurocrine Biosciences (NBIX)

STOCK Act disclosures House disclosures

The most recent congressional trade disclosed in Neurocrine Biosciences is a sale by Lisa C. McClain (house, MI), dated 17 Jun 2025.

Date Member Type Amount
17 Jun 2025 filed 13 Aug 2025 Lisa C. McClain house · Republican–MI Sale $1K–$15K
11 Jun 2025 filed 13 Aug 2025 Lisa C. McClain house · Republican–MI Purchase $1K–$15K

Neurocrine Biosciences (NBIX): frequently asked questions

From live data

Have Neurocrine Biosciences insiders bought or sold shares recently?

In the 90 days to 22 Oct 2026, Neurocrine Biosciences insiders reported 4 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 13 Feb 2026, show no open-market purchase. A further 24 filings were grants, awards, gifts or exercises rather than open-market trades.

How many institutions hold Neurocrine Biosciences?

10 of the 45 institutional funds we track reported a Neurocrine Biosciences position for the quarter ended 30 Jun 2026, per SEC Form 13F filings.

Has Neurocrine Biosciences had fails-to-deliver recently?

Yes. The most recent SEC fails-to-deliver record for Neurocrine Biosciences is dated 11 Sep 2026, when 1,221 shares failed to deliver.

When did Neurocrine Biosciences last report earnings?

Neurocrine Biosciences last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of $1.39; no next date is announced in SEC filings yet.

What exchange is Neurocrine Biosciences listed on?

Neurocrine Biosciences trades on NASDAQ under the ticker NBIX.

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. House disclosuresU.S. House of Representatives financial disclosures
  7. SEC EDGARValuation computed from SEC EDGAR filings